Joao S.
- Country
- Portugal
- Department
- Neurology
Research Overview
- Investigation of RO7121932 Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics in Multiple Sclerosis Patients
- Efficacy and Safety of Remibrutinib in Patients with Secondary Progressive Multiple Sclerosis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study
- Phase 3 Randomized Double‑Blind Study of Orelabrutinib vs Placebo on Disability Progression in Non‑Active Secondary Progressive Multiple Sclerosis
Data & Insights
Has run more than one trial at 274 of 604 partner sites.
Specializations
Metabolic Disorders
This investigator specializes in treating various forms of hypertriglyceridemia, including severe cases and rare genetic conditions like Familial Chylomicronemia Syndrome (FCS).
- Triglyceride Management
- Lipid Metabolism Disorders
- Genetic Lipid Disorders
Their research explores innovative therapeutic approaches for managing abnormal lipid levels in patients with various metabolic conditions.
Cardiovascular Medicine
The investigator focuses on the intersection of atherosclerotic cardiovascular disease and metabolic disorders, particularly in relation to lipid management.
- Atherosclerosis Treatment
- Cardiovascular Risk Management
- Preventive Cardiology
Their work addresses the complex relationship between cardiovascular health and metabolic dysfunction.
Diabetes Management
The investigator has expertise in treating Type 2 Diabetes, with particular emphasis on optimizing treatment strategies for patients with concurrent overweight conditions.
- Insulin Therapy Optimization
- Glycemic Control
- Weight Management in Diabetes
Their research explores innovative approaches to diabetes management, including combination therapies and dose optimization strategies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.